Acrylamide Neurotoxicity: Neurological, Morhological and Molecular Endpoints in Animal Models

  • Richard M. LoPachin
Part of the Advances in Experimental Medicine and Biology book series (AEMB, volume 561)


Acrylamide (AA) monomer is used in numerous chemical industries and is a contaminant in potato- and grain-based foods prepared at high temperatures. Although experimental animal studies have implicated carcinogenicity and reproductive toxicity as possible consequences of exposure, neurotoxicity is the only outcome identified by epidemiological studies of occupationally exposed human populations. Neurotoxicity in both humans and laboratory animals is characterized by ataxia and distal skeletal muscle weakness. Early neuropathological studies suggested that AA neurotoxicity was mediated by distal axon degeneration. However, more recent electrophysiological and quantitative morphometric analyses have identified nerve terminals as primary sites of AA action. A resulting defect in neurotransmitter release appears to be the pathophysiological basis of the developing neurotoxicity. Corresponding mechanistic research suggests that AA impairs release by adducting cysteine residues on functionally important presynaptic proteins. In this publication we provide an overview of recent advances in AA research. This includes a discussion of the cumulative nature of AA neurotoxicity and the putative sites and molecular mechanisms of action.

Key words

toxic neuropathy distal axonopathy protein adducts nerve terminals neurotoxicity 


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. Abelli L., Ferri G.-L., Astolfi M., Conte, B., Geppetti P., Parlani M., Dahl, D., Polak, J.M. and Maggi, C.A. 1991, Acrylamide-induced visceral neuropathy: evidence for the involvement of capsaicin-sensitive nerve to the rat urinary bladder. Neuroscience 41: 311–321.CrossRefGoogle Scholar
  2. Abou-Donia, M.B., Ibrahim S.M., Corcoran J.J., Lack L., Friedman, M.A. and Lapadula, D.M. 1993, Neurotoxicity of glycidamide, an acrylamide metabolite, following intraperitoneal injections in rats. J. Toxicol. Environ. Health 39: 447–464.Google Scholar
  3. Amaratunga, A., Leeman, S.E., Kosik, K.S. and Fine, R.E. 1995, Inhibition of kinesin synthesis in vivo inhibits the rapid transport of representative proteins for three transport vesicle classes into the axon. J. Neurochem. 64: 2374–2376.CrossRefGoogle Scholar
  4. Barber, D., Hunt, J.R., Ehrich, M., Lehning, E.J. and LoPachin, RM. 2001, Metabolism, toxicokinetics and hemoglobin adduct formation in rats following subacute and subchronic acrylamide dosing. NeuroToxicology, 22:341–353.CrossRefGoogle Scholar
  5. Becalski, A., Lau, B., Lewis, D. and Seaman, S. 2002, Acrylamide in food: occurrence and sources. Presented at the Annual Meeting of AOAC International, September 26.Google Scholar
  6. Beckers, C.J.M., Block, M.R., Glick, B.S., Rothman, J.E and Balch, W.E. 1989, Vesicular transport between the endoplasmic reticulum and the Golgi stack requires the NEM-sensitive fusion protein. Nature 339: 397–398.CrossRefGoogle Scholar
  7. Bergmark, E., Calleman, C.J. and Costa, L.G. 1991, Formation of hemoglobin adducts of acrylamide and its epoxide metabolite glycidamide in the rat. Toxicol. Appl. Pharmacol. 111: 352–363.CrossRefGoogle Scholar
  8. Bergmark, E., Calleman, C.J., He, F. and Costa, L.G. 1993, Determination of hemoglobin adducts in humans occupationally exposed to acrylamide. Toxicol. Appl. Pharmacol. 120: 45–54.CrossRefGoogle Scholar
  9. Brat, D.J. and Brimijion, S. 1993, Acrylamide and glycidamide impair neurite outgrowth in differentiating N1E.115 neuroblastoma without disturbing rapid bi-directional transport of organelles observed by video microscopy. J. Neurochem. 60: 2145–2152.Google Scholar
  10. Brimijion, W.S. and Hammond, P.I. 1985, Acrylamide neuropathy in the rat: effects on energy metabolism in sciatic nerve. Mayo Clin. Proc. 60: 3–8.Google Scholar
  11. Bull, R.J., Robinson, M., Laurie, R.D., Stoner, G.D., Greisiger, E., Meier, J.R. and Stober, J. 1984a, Carcinogenic effects of acrylamide in sencar and A/J mice. Cancer Res 44: 107–111.Google Scholar
  12. Bull, R.J., Robinson, M. and Stoner, G.D. 1984b, Carcinogenic activity of acrylamide in the skin and lung of Swiss-ICR mice. Cancer Lett 24: 209–212.CrossRefGoogle Scholar
  13. Burek, J.D., Albee, R.R., Beyer, J.E., Bell, T.J., Carreon, R.M., Morden, D.C., Wade, C.E., Hermann, E.A. and Gorzinski, S.J. 1980, Subchronic toxicity of acrylamide administered to rats in drinking water followed by up to 144 days of recovery. J. Environ. Pathol. Toxicol. 4: 157–182.Google Scholar
  14. Calleman, C.J. The metabolism and pharmacokinetics of acrylamide: implications for mechanisms of toxicity and human risk estimation. Drug Met. Rev. 28: 527–590.Google Scholar
  15. Cavanagh, J.B. 1964, The significance of the “dying-back” process in experimental and human neurological disease. Int. Rev. Exp. Pathol. 3: 219–267.Google Scholar
  16. Cavanagh, J.B. 1979, The dying back process. Arch. Pathol. Lab. Med. 103: 659–664.Google Scholar
  17. Cavanagh, J.B. 1982, The pathokinetics of acrylamide intoxication: a reassessment of the problem. Neuropath Appl Neurobiol 8: 315–336.Google Scholar
  18. Cavins, J.F. and Friedman, M. 1968, Specific modification of protein sulfhydryl groups with α,β-unsaturated compounds. J. Biol. Chem. 243: 3357–3360.Google Scholar
  19. Chapman, E.R., An, S., Barton, N. and Jahn, R. 1994, SNAP-25, a t-SNARE which binds to both syntaxin and synaptobrevin via domains that may form coiled coils. J. Biol. Chem. 269: 27427–27432.Google Scholar
  20. Chretien, M., Patey, G., Souyri, F. and Droz, B. 1981, Acrylamide-induced neuropathy and impairment of axonal transport of proteins. II. Abnormal accumulations of smooth endoplasmic reticulum as sites of focal retention of fast transported proteins. Electron microscope radioautographic study. Brain Res. 205: 15–28.CrossRefGoogle Scholar
  21. Costa, L.G., Deng, H., Gregotti, C., Manzo, L., Faustman, E.M., Bergmark, E. and Calleman C.J. 1992, Comparative studies on the neuro-and reproductive toxicity of acrylamide and its epoxide metabolite glycidamide in the rat. NeuroToxicology 13: 219–224.Google Scholar
  22. Costa, L.G., Deng, H., Calleman, C.J. and Bergmark, E. 1995, Evaluation of the neurotoxicity of glycidamide, an epoxide metabolite of acrylamide: behavioral, neurochemical and morphological studies. Toxicology 98: 151–161.CrossRefGoogle Scholar
  23. Crofton, K.M., Padilla, S., Tilson, H.A., Anthony, D.C., Raymer, J.H. and MacPhail, R.C. 1996, The impact of dose rate on the neurotoxicity of acrylamide: The interaction of administered dose, target tissue concentrations, tissue damage, and functional effects. Tox. Appl. Pharmacol. 139: 163–176.CrossRefGoogle Scholar
  24. DeGrandchamp, R.L. and Lowndes, H.E. 1990, Early degeneration and sprouting at the rat neuromuscular junction following acrylamide administration. Neuropath. Appl. Neurobiol. 16: 239–254.Google Scholar
  25. DeGrandchamp, R.L., Reuhl, K.R. and Lowndes, H.E. 1990, Synaptic terminal degeneration and remodeling at the rat neuromuscular junction resulting from a single exposure to acrylamide. Tox Appl Pharmacol 105: 422–433.CrossRefGoogle Scholar
  26. De Rojas, T.C, and Goldstein, B.D. 1987, Primary afferent terminal function following acrylamide: alterations in the dorsal root potential and reflex. Tox. Appl. Pharmacol. 88: 175–182.CrossRefGoogle Scholar
  27. Deng, H., He, S. and Zhang, S. 1993, Quantitative measurements of vibration threshold in healthy adults and acrylamide workers. Int. Arch. Occup. Environ. Health 65: 53–56.CrossRefGoogle Scholar
  28. Dixit, R., Sas, M., Seth, P.K. and Mukhtar, H. 1986, Interaction of acrylamide with bovine serum albumin. Environ. Res. 40: 365–371.CrossRefGoogle Scholar
  29. Dschida, W.J.A, and Bowman, B.J. 1995, The vacuolar ATPase: sulfite stabilization and the mechanism of nitrate inactivation. J. Biol. Chem. 270: 1557–1563.CrossRefGoogle Scholar
  30. Edwards, P.M. 1975, The distribution and metabolism of acrylamide and its neurotoxic analogues in rats. Biochem. Pharmacol. 24: 1277–1282.CrossRefGoogle Scholar
  31. Edwards, P.M. and Parker, V.H. 1977, A simple, sensitive and objective method for early assessment of acrylamide neuropathy in rats. Tox. Appl. Pharmacol. 40: 589–591.CrossRefGoogle Scholar
  32. Erecinska, M. and Nelson, D. 1994, Effects of 3-nitropropionic acid on synaptosomal energy and transmitter metabolism: relevance to neurodegenerative brain diseases. J. Neurochem. 63: 1033–1041.CrossRefGoogle Scholar
  33. Friedman, M.A., Dulak, L.H. and Stedham, M.A. 1995, A lifetime oncogenicity study in rats with acrylamide. Fund. Appl. Toxicol. 27: 95–105.CrossRefGoogle Scholar
  34. Friedman, M., 1973, Nucleophilic additions. In: The Chemistry and Biochemistry of the Sulfhydryl Group in Amino Acids, Peptides, and Proteins, Chapter 4. New York: Pergamon Press, 1973. pp. 88–134.Google Scholar
  35. Garland, T.O. and Patterson M. 1967, Six cases of acrylamide poisoning. Brit Med J 4: 134–138.CrossRefGoogle Scholar
  36. Gilbert, H.F. 1982, Biological disulfides: the third messenger? J. Biol. Chem. 257: 12086–12091.Google Scholar
  37. Ghetti, B., Wisneiwski, H.M., Cook, R.D. and Schaumburg, H.H. 1973, Changes in the CNS after acute and chronic acrylamide intoxication. Am. J. Pathol. 70: 78A.Google Scholar
  38. Goldstein, B.D. and Lowndes, H.E. 1979, Spinal cord defect in the peripheral neuropathy resulting from acrylamide. NeuroToxicology 1: 75–87.Google Scholar
  39. Goldstein, B.D. and Lowndes, H.E. 1981, Group Ia primary afferent terminal defect in cats with acrylamide neuropathy. NeuroToxicology 2: 297–312.Google Scholar
  40. Hashimoto, K. and Aldridge, W.N. 1970, Biochemical studies on acrylamide, a neurotoxic agent. Biochem Pharmacol 19, 2591–2604.CrossRefGoogle Scholar
  41. He, F., Zhang, S. and Wang, H. 1989, Neurological and electroneuromyographic assessment of the adverse effects of acrylamide on occupationally exposed workers. Scand. J. Work Environ. Health 15: 125–129.Google Scholar
  42. Hinson, J.A. and Roberts, D.W. 1992, Role of covalent and noncovalent interactions in cell toxicity: effects on proteins. Annu. Rev. Pharmacol. Toxicol. 32: 471–510.CrossRefGoogle Scholar
  43. Jahn, R. and Sudhof, T.C. 1999, Membrane fusion and exocytosis. Ann. Rev. Biochem. 68: 863–911.CrossRefGoogle Scholar
  44. Jennekens, F.G.I., Veldman, H., Schotman, P. and Gispen, W.H. 1979, Sequence of motor nerve terminal involvement in acrylamide neuropathy. Acta Neuropath 46: 57–63.CrossRefGoogle Scholar
  45. Johnson, K.A., Gorzinski, S.J., Bodner, K.M., Campbell, R.A., Wolf, C.H., Friedman, M.A. and Mast, R.W. 1986, Chronic toxicity and oncogenicity study on acrylamide incorporated in the drinking water of Fischer 344 rats. Toxicol. Appl. Pharmacol. 85: 154–168.CrossRefGoogle Scholar
  46. Kemplay, S, and Cavanagh, J.B. 1984a, Effects of acrylamide and other sulfhydryl compound in vivo and in vitro on staining of motor nerve terminals by the zinc iodide-osmium technique. Musc Nerve 7: 94–100.CrossRefGoogle Scholar
  47. Kemplay, S. and Cavanagh, J.B. 1984b, Effects of acrylamide and some other sulfhydryl reagents on spontaneous and pathologically induced terminal sprouting from motor end-plates. Musc Nerve 7: 101–109.CrossRefGoogle Scholar
  48. Kuperman, A.S. 1958, Effects of acrylamide on the central nervous system of the cat. J. Pharmacol Exp Ther 123: 180–192.Google Scholar
  49. Lasek, R.J., Garner, J.A. and Brady, S.T. 1984, Axonal transport of the cytoplasmic matrix. J. Cell Biol 99: 212–221.CrossRefGoogle Scholar
  50. Lehning, E.J., LoPachin, R.M., Matthew, J. and Eichberg, J. 1994, Changes in Na-K ATPase and protein kinase C activities in peripheral nerve of acrylamide-treated rats. J. Tox. Environ. Health 42: 331–342.CrossRefGoogle Scholar
  51. Lehning, E.J., Gaughan, C.L. and LoPachin, R.M. 1997, Acrylamide intoxication modifies in vitro responses of peripheral nerve axonal to anoxia. J Periph Nerv Sys 2: 165–174.Google Scholar
  52. Lehning, E.J., Persaud, A., Dyer, K.R., Jortner, B.S. and LoPachin, R.M. 1998, Biochemical and Morphologic characterization of acrylamide peripheral neuropathy. Toxicol. Appl. Pharmacol. 151: 211–221.CrossRefGoogle Scholar
  53. Lehning, E.J., Balaban, C.D., Ross, J.F., Reid, M.L. and LoPachin, R.M. 2002a, Acrylamide neuropathy. I. Spatiotemporal characteristics of nerve cell damage in rat cerebellum. NeuroToxicology 23: 397–414.CrossRefGoogle Scholar
  54. Lehning, E.J., Balaban, C.D., Ross, J.F. and LoPachin, R.M. 2002b, Acrylamide neuropathy. II. Spatiotemporal characteristics of nerve cell damage in rat brainstem and spinal cord. NeuroToxicology 23: 415–429.CrossRefGoogle Scholar
  55. Lehning, E.J., Balaban, C.D., Ross, J.F. and LoPachin, R.M. 2003, Acrylamide neuropathy. III. Spatiotemporal characteristics of nerve cell damage in rat forebrain. NeuroToxicology 24: 124–136.Google Scholar
  56. Lin, R.C. and Scheller, R.H. 2000, Mechanisms of synaptic vesicle exocytosis. Annu Rev Cell Dev Biol 16: 19–49.CrossRefGoogle Scholar
  57. Lipton, S.A, Choi, Y.B., Pan, Z.H., Lei, S.Z., Chen, H.S.V., Sucher, N.J., Loscalzo, J., Singel, D.J. and Stamier, J.S. 1993, A redox-based mechanism for the neuroprotective and neurodestructive effects of nitric oxide and related nitroso-compounds. Nature 364: 626–631.CrossRefGoogle Scholar
  58. Littleton, J.T., Chapman, E.R., Kreber, R., Garment, M.B., Carlson, S.D. and Ganetzky, B. 1998, Temperature-sensitive paralytic mutations demonstrate that synaptic exocytosis requires SNARE complex assembly and disassembly. Neuron 21: 401–413.CrossRefGoogle Scholar
  59. Lombet, A., Laduron, P., Mourre, C., Jacomet, Y. and Lazdunski, M. 1986, Axonal transport of Na, K-ATPase identified as an ouabain binding site in rat sciatic nerve. Neurosci Letts 64: 177–183.CrossRefGoogle Scholar
  60. LoPachin, R.M., Moore, R.W., Menahan, L.A. and Peterson, R.E. 1984, Glucose-dependent lactate production by homogenates of neuronal tissues prepared from rats treated with 2,4-dithiobiuret, acrylamide, p-bromophenylacetylurea and 2,5-hexanedione, Neuro Toxicology 5: 25–36.Google Scholar
  61. LoPachin, R.M. and Lehning, E.J. 1994, Acrylamide-induced distal axon degeneration: A proposed mechanism of action. NeuroToxicology 15: 247–260.Google Scholar
  62. LoPachin, R.M., Lehning, E.J., Opanashuk, L.A. and Jortner, B.S. 2000, Rate of neurotoxicant exposure determines morphologic manifestations of distal axonopathy. Tox Appl Pharmacol 167: 75–86.CrossRefGoogle Scholar
  63. LoPachin, R.M., Ross, J.F. and Lehning, E.J. 2002a, Nerve terminals as the primary site of acrylamide action. NeuroToxicology 23: 43–59.CrossRefGoogle Scholar
  64. LoPachin, R.M., Ross, J.F., Reid, M.L., Dasgupta, S., Mansukhani, S. and Lehning, E.J. 2002b, Neurological evaluation of toxic axonopathies in rats: acrylamide and 2,5-hexanedione. NeuroToxicology 23: 95–110.CrossRefGoogle Scholar
  65. LoPachin, R.M., Balaban, C.D. and Ross, J.F. 2003, Acrylamide axonopathy revisited. Tox. Appl. Pharmacol. 188:135–153.CrossRefGoogle Scholar
  66. LoPachin, R.M., Schwarcz, A.I., Gaughan, C.L., Mansukhani, S. and Das, S. 2004, In vivo and in vitro effects of acrylamide on synaptosomal neurotransmitter uptake and release. NeuroToxicology 25: 349–363.CrossRefGoogle Scholar
  67. Lowndes, H.E. and Baker, T. 1976, Studies on drug-induced neuropathies. III. Motor nerve deficit in cats with experimental acrylamide neuropathy. Europ. J. Pharmacol. 35: 177–184.CrossRefGoogle Scholar
  68. Lowndes, H.E., Baker, T., Michelson, L.P. and Vincent-Ablazey, M. 1978a, Attenuated dynamic responses of primary endings of muscle spindles: A basis for depressed tendon responses in acrylamide neuropathy. Ann. Neurol. 3: 433–437.CrossRefGoogle Scholar
  69. Lowndes, H.E., Baker, T., Cho, E.-S. and Jortner, B.S. 1978b, Position sensitivity of de-efferented muscle spindles in experimental acrylamide neuropathy. J. Pharmacol. Exp. Ther. 205: 40–48.Google Scholar
  70. Malhotra, V., Orci, L., Glick, B.S., Block, M.R. and Rothman, J.E. 1988, Role of an N-ethylmaleimide-sensitive transport component in promoting fusion of transport vesicles with cisternae of the Golgi stack. Cell 54: 221–227.CrossRefGoogle Scholar
  71. Mastrogiacomo, A. and Gundersen, C.B. 1995, The nucleotide and deduced amino acid sequence of a rat cysteine string protein. Mole. Brain Res. 28: 12–18.CrossRefGoogle Scholar
  72. Mata, M., Datta, S., Jin, C.F. and Fink, D.J. 1993, Differential axonal transport of individual Na,K-ATPase catalytic (α) subunit isoforms in rat sciatic nerve. Brain Res. 618: 295–298.CrossRefGoogle Scholar
  73. Medrano, C.J. and LoPachin, R.M. 1989, Effects of acrylamide and 2,5-hexanedione on brain mitochondrial respiration. NeuroToxicology 10: 249–256.Google Scholar
  74. Miller, M.S., Carter, D.E. and Sipes, I.G. 1982, Pharmacokinetics of acrylamide in Fisher-334 rats. Tox Appl Pharmacol 63: 36–44.CrossRefGoogle Scholar
  75. Moser, V.C., Anthony, D.C., Sette, W.F. and MacPhail, R.C. 1992, Comparison of subchronic neurotoxicity of 2-hydroxyethyl acrylate and acrylamide in rats. Fundam. Appl. Toxicol. 18: 343–352.CrossRefGoogle Scholar
  76. Munch, G., Lincoln, J., Maynard, K.I., Belai, A. and Burnstock, G. 1994, Effects of acrylamide on cotransmission in perivascular sympathetic and sensory nerves. J. Auton. Nerv. Sys. 49: 197–205.CrossRefGoogle Scholar
  77. Nichols, B.J. and Pelham, H.R.B. 1998, SNAREs and membrane fusion in the Golgi apparatus. Biochen. Biophys. Acta 1404: 9–31.CrossRefGoogle Scholar
  78. Pan, Z.H., Bahring, R., Grantyn, R. and Lipton, S.A. 1995, Differential modulation by sulfhydryl redox agents and glutathione of GABA-and glycine-evoked currents in rat retinal ganglion cells. J. Neurosci. 15: 1384–1391.Google Scholar
  79. Prineas, J. 1969, The pathogenesis of dying-back polyneuropathies. Part II. An ultrastructural study of experimental acrylamide intoxication in the cat. J. Neuropath. Exp. Neurol. 28: 598–621.Google Scholar
  80. Rosen, J. and Hellenas, K.E. 2002, Analysis of acrylamide in cooked foods by liquid chromatography and tandem mass spectrometry. The Analyst 127: 880–882.CrossRefGoogle Scholar
  81. Rothman, J.E. 1994, Mechanisms of intracellular protein transport. Nature 372: 55–63.CrossRefGoogle Scholar
  82. Sabri, M.I. and Spencer, P.S. 1980, Toxic distal axonopathy: biochemical studies and hypothetical mechanisms. In: Spencer PS, Schaumburg HH, editors. Experimental and clinical neurotoxicology. Baltimore, MD: Williams & Wilkins, p. 206–219.Google Scholar
  83. Sanders, R.A., Zyzak, D.V., Stojanovic, M., Tallmadge, D.H., Eberhart, B.L. and Ewald, D.K. 2002, An LC/MS acrylamide method and it’s use in investigating the role of asparagine. Presented at the Annual Meeting of AOAC International, September 26.Google Scholar
  84. Schaumburg, H.H., Wisniewski, H.M. and Spencer, P.S. 1974, Ultrastructural studies of the dying-back process. I. Peripheral nerve terminal and axon degeneration in systemic acrylamide intoxication. J. Neuropath. Exp. Neurol. 33: 260–284.CrossRefGoogle Scholar
  85. Sega, G.A., Valdivia, Alcota, R.P., Tancogco, C.P. and Brimer, P. 1989, Acrylamide binding to the DNA and protamine of spermiogenic stages in the mouse and its relationship to genetic damage. Mutat. Res. 216: 221–230.Google Scholar
  86. Shell, L., Rozum, M., Jortner, B.S. and Ehrich, M. 1992, Neurotoxicity of acrylamide and 2,5-hexanedione in rats evaluated using a functional observational battery and pathological examination. Neurotox. Teratol. 14: 273–283.CrossRefGoogle Scholar
  87. Sickles, D.W., Fowler, S.R. and Testino, A.R. 1990, Effects of neurofilamentous axonopathyproducing neurotoxicants on in vitro production of ATP by brain mitochondria. Brain Res. 528: 25–31.CrossRefGoogle Scholar
  88. Sickles, D.W., Stone, J.D. and Friedman, M.A. 2002, Fast axonal transport: a site of acrylamide neurotoxicity. NeuroToxicology 23: 223–251.CrossRefGoogle Scholar
  89. Spencer, P.S. and Schaumburg, H.H. 1974a, A review of acrylamide neurotoxicity. Part I. Properties, uses and human exposure.. Can. J. Neurol. Sci. 1: 151–169.Google Scholar
  90. Spencer, P.S. and Schaumburg, H.H. 1974b, A review of acrylamide neurotoxicity. Part II. Experimental animal neurotoxicity and pathologic mechanisms. Can J Neurol Sci 1: 170–192.Google Scholar
  91. Spencer, P.S. and Schaumburg, H.H. 1976, Central-peripheral distal axonopathy-The pathology of dying-back polyneuropathies. In: Progress in Neuropathology. Zimmerman H., ed., New York, Grune & Stratton, 3: 253–276.Google Scholar
  92. Spencer, P.S. and Schaumburg, H.H. 1977a, Ultrastructural studies of the dying-back process. III. The evolution of experimental peripheral giant axonal degeneration. J Neuropath Exp Neurol 36: 276–299.Google Scholar
  93. Spencer, P.S. and Schaumburg, H.H. 1977b, Ultrastructural studies of the dying-back process. IV. Differential vulnerability of PNS and CNS fibers in experimental central-peripheral distal axonopathy. J. Neuropath. Exp. Neurol. 36: 300–320.Google Scholar
  94. Sumner, S., Fennell, T., Moore, T.A., Chanas, B., Gonzalez, F. and Ghanayem, B.I. 1999, Role of cytochrome P450 2E1 in the metabolism of acrylamide and acrylonitrile in mice. Chem Res Toxicol 12: 1110–1116.CrossRefGoogle Scholar
  95. Suzuki, K. and Pfaff, L. 1973, Acrylamide neuropathy in rats. An electron microscopic study of degeneration and regeneration. Acta Neuropathol. 24: 197–203.CrossRefGoogle Scholar
  96. Tagaya, M., Wilson, D.W., Brunner, M., Arango, N. and Rothman, J.E. 1993, Domain structure of an N-ethylmaleimide-sensitive fusion protein involved in vesicular transport. J. Biol. Chem. 268: 2662–2666.Google Scholar
  97. Tareke, E., Rydberg, P., Karlsson, P., Eriksson, S. and Tornqvist, M. 2000, Acrylamide: A cooking carcinogen? Chem. Res. Toxicol. 13: 517–522.CrossRefGoogle Scholar
  98. Tareke, E., Rydberg, P., Karlsson, P., Eriksson, S. and Tornqvist, M. 2002, Analysis of acrylamide, a carcinogen formed in heated foodstuffs. J. Agric. Food Chem. 50: 4998–5006.CrossRefGoogle Scholar
  99. Tilson, H.A. and Cabe, P.A. 1979, The effects of acrylamide given acutely or in repeated doses on fore-and hindlimb function of rats. Tox. Appl. Pharmacol. 47; 253–260.CrossRefGoogle Scholar
  100. Tolar, L.A. and Pallanck, L. 1998, NSF function in neurotransmitter release involves rearrangement of the SNARE complex downstream of synaptic vesicle docking. J. Neurosci. 18: 10250–10256.Google Scholar
  101. Tsujihata, M., Engel, A.G. and Lambert, E.H. 1974, Motor end-plate fine structure in acrylamide dying-back neuropathy: A sequential morphometric study. Neurology 24: 849–856.Google Scholar
  102. Tyl, R.W., Marr, M.C., Myers, C.B., Ross, W.P. and Friedman, M.A. 2000a, Relationship between acrylamide reproductive and neurotoxicity in male rats. Reprod Toxicol 14: 147–157.CrossRefGoogle Scholar
  103. Whiteheart, S.W., Rossnagel, K., Buhrow, S.A., Brunner, M., Jaenicke, R. and Rothman, J.E. 1994, N-Ethylmaleimide-sensitive fusion protein: a trimeric ATPase whose hydrolysis of ATP is required for membrane fusion. J. Cell Biol. 126: 945–954.CrossRefGoogle Scholar
  104. Working, P., Bentley, K., Hurtt, M. and Mohr, K. 1987, Comparison of the dominant lethal effects of acrylonitrile and acrylamide in male Fischer 344 rats. Mutagenesis 2: 215–220.Google Scholar

Copyright information

© Springer Science+Business Media, Inc. 2005

Authors and Affiliations

  • Richard M. LoPachin
    • 1
  1. 1.Department of AnesthesiologyAlbert Einstein College of MedicineBronx

Personalised recommendations